Matthew J Walter

List of Publications by Year
in descending order

116 papers	17,390 citations	71102 41 h-index	37204 96 g-index
121 all docs	121 docs citations	121 times ranked	24139 citing authors

#	Article	IF	Citations
1	Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502, 333-339.	27.8	3,695
2	Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481, 506-510.	27.8	1,795
3	Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 2014, 20, 1472-1478.	30.7	1,533
4	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell, 2012, 150, 264-278.	28.9	1,365
5	Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1090-1098.	27.0	688
6	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	27.8	685
7	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
8	Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 2012, 44, 53-57.	21.4	513
9	Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 2011, 25, 1153-1158.	7.2	483
10	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology, 2014, 10, e1003665.	3.2	400
11	Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 379-392.	16.8	330
12	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	27.0	322
13	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	7.4	302
14	Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia, 2013, 27, 1275-1282.	7.2	260
15	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing InÂVivo. Cancer Cell, 2015, 27, 631-643.	16.8	259
16	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	12.8	243
17	Acquired copy number alterations in adult acute myeloid leukemia genomes. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12950-12955.	7.1	231
18	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207

#	Article	IF	Citations
19	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
20	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
21	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	28.9	177
22	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	6.4	177
23	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. New England Journal of Medicine, 2021, 384, 924-935.	27.0	170
24	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165
25	Interleukin 12 P40 Production by Barrier Epithelial Cells during Airway Inflammation. Journal of Experimental Medicine, 2001, 193, 339-352.	8.5	152
26	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	12.8	150
27	Identification of a Novel <emph type="ital">TP53</emph> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. JAMA - Journal of the American Medical Association, 2011, 305, 1568.	7.4	146
28	Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Research, 2018, 78, 5363-5374.	0.9	117
29	Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing. PLoS Genetics, 2014, 10, e1004462.	3.5	115
30	U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia, 2015, 29, 909-917.	7.2	107
31	Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nature Communications, 2017, 8, 14060.	12.8	99
32	Splicing factor gene mutations in hematologic malignancies. Blood, 2017, 129, 1260-1269.	1.4	99
33	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	1.4	94
34	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
35	Targeted Inhibition of Interferon-Î³-dependent Intercellular Adhesion Molecule-1 (ICAM-1) Expression Using Dominant-Negative Stat1. Journal of Biological Chemistry, 1997, 272, 28582-28589.	3.4	90
36	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia, 2017, 31, 872-881.	7.2	87

#	Article	IF	Citations
37	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
38	Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARÂ. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12513-12518.	7.1	81
39	Genetics of progression from MDS to secondary leukemia. Blood, 2020, 136, 50-60.	1.4	80
40	Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood, 2011, 117, 1530-1539.	1.4	72
41	â€˜CHIPâ€™ping away at clonal hematopoiesis. Leukemia, 2016, 30, 1633-1635.	7.2	48
42	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 2018, 3, .	5.0	48
43	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Experimental Hematology, 2016, 44, 603-613.	0.4	44
44	Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica, 2019, 104, e388-e392.	3.5	40
45	The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia, 2014, 28, 1242-1251.	7.2	35
46	Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood, 2018, 131, 2402-2405.	1.4	30
47	Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations. Cancer Research, 2021, 81, 4499-4513.	0.9	28
48	Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing. Trends in Cancer, 2015, 1, 231-241.	7.4	25
49	Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood, 2017, 129, 1397-1401.	1.4	24
50	A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. Cell Chemical Biology, 2021, 28, 1145-1157.e6.	5.2	24
51	Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells. PLoS ONE, 2017, 12, e0170470.	2.5	23
52	Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood, 2014, 124, 3887-3895.	1.4	20
53	Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia, 2018, 32, 1874-1878.	7.2	18
54	Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia, 2022, 36, 935-945.	7.2	18

#	Article	IF	Citations
55	Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells. Experimental Hematology, 2015, 43, 319-330.e10.	0.4	15
56	Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 32-49.	5.0	14
57	Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood, 2013, 122, e44-e51.	1.4	13
58	Failure to Detect Mutations in U2AF1 due to Changes in the GRCh38 Reference Sequence. Journal of Molecular Diagnostics, 2022, 24, 219-223.	2.8	13
59	Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood, 2018, 131, 1032-1035.	1.4	12
60	Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice. Cell Reports, 2021, 36, 109626.	6.4	12
61	Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression. Blood, 2016, 128, 959-959.	1.4	12
62	Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. Blood Cancer Discovery, 2022, 3, 330-345.	5.0	10
63	U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	9
64	Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes. Blood, 2010, 116, 99-99.	1.4	9
65	A Pilot Study of CPX-351 (Vyxeos Â©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome. Blood, 2021, 138, 540-540.	1.4	8
66	Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromes. Experimental Hematology, 2022, 110, 47-59.	0.4	7
67	Expression of a bcr-1 isoform of RARÎ±-PML does not affect the penetrance of acute promyelocytic leukemia or the acquisition of an interstitial deletion on mouse chromosome 2. Blood, 2007, 109, 1237-1240.	1.4	6
68	Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia, 2016, 30, 2422-2426.	7.2	6
69	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532.	1.4	6
70	Preclinical Activity of Splicing Modulators in U2AF1 Mutant MDS/AML. Blood, 2015, 126, 1653-1653.	1.4	6
71	POU4F1 Is Associated with t(8;21) AML and Contributes Directly to Its Unique Transcriptional Signature.. Blood, 2009, 114, 2623-2623.	1.4	6
72	What came first: MDS or AML?. Blood, 2015, 125, 1357-1358.	1.4	5

#	Article	IF	Citations
73	Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice. Leukemia Research, 2020, 96, 106428.	0.8	5
74	BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia.. Blood, 2009, 114, 1102-1102.	1.4	5
75	The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML. Blood, 2013, 122, 5-5.	1.4	5
76	High-Resolution Comparative Genomic Hybridization of Mirna Genes In Therapy-Related AML Identifies a Somatic Deletion of MiR-223. Blood, 2010, 116, 2759-2759.	1.4	5
77	Pancytopenia Secondary to Oxalosis in a 23-Year-Old Woman. Blood, 1998, 91, 4394-4394.	1.4	5
78	Del(5q): gene dosage matters. Blood, 2007, 110, 473-474.	1.4	4
79	Antecedent CHIP in CML?. Blood, 2017, 129, 3-4.	1.4	4
80	Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics.. Blood, 2004, 104, 142-142.	1.4	4
81	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood, 2021, 138, 1521-1521.	1.4	4
82	IL-1Î² expression in bone marrow dendritic cells is induced by TLR2 agonists and regulates HSC function. Blood, 2022, 140, 1607-1620.	1.4	4
83	Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study. Blood, 2018, 132, 4370-4370.	1.4	3
84	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. Blood, 2015, 126, 610-610.	1.4	3
85	Clinical Implications of Spliceosome Mutations: Epidemiology, Clonal Hematopoiesis, and Potential Therapeutic Strategies. Blood, 2016, 128, SCI-19-SCI-19.	1.4	3
86	Reduced HSPA9B Expression, a 5q31.2 Candidate Gene, in Primary Human CD34+ Cells Recapitulates Features of Ineffective Hematopoiesis Observed in MDS.. Blood, 2007, 110, 116-116.	1.4	3
87	DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression. Blood, 2016, 128, 1050-1050.	1.4	3
88	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. Blood, 2020, 136, 32-33.	1.4	2
89	High Resolution Array-Based CGH and SNP Studies of AML Genomes.. Blood, 2007, 110, 107-107.	1.4	2
90	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing in Transgenic Mice. Blood, 2014, 124, 827-827.	1.4	2

#	Article	IF	Citations
91	Characterization of Hematopoiesis in Tp53 R172H Mutant Mice. Blood, 2015, 126, 2452-2452.	1.4	2
92	Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies. Blood, 2020, 136, 4-5.	1.4	2
93	Comprehensive Genomic Copy Number and Sequence Analysis of 28 Chromosome 5q31.2 Candidate Genes in De Novo MDS.. Blood, 2007, 110, 117-117.	1.4	1
94	B-Cell Progenitors Are Reduced in Hspa9 haploinsufficient Mice,. Blood, 2011, 118, 3829-3829.	1.4	1
95	A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. Blood, 2015, 126, 1686-1686.	1.4	1
96	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
97	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 2379-2380.	27.0	0
98	Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH).. Blood, 2005, 106, 2350-2350.	1.4	0
99	DNA Sequence of the Cancer Genome of a Patient with Therapy-Related Acute Myeloid Leukemia. Blood, 2010, 116, 580-580.	1.4	0
100	Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome. Blood, 2010, 116, 608-608.	1.4	0
101	Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing. Blood, 2010, 116, 299-299.	1.4	0
102	Dysfunctional Double-Strand DNA Break Repair In Primary t-AML/t-MDS Myeloblasts.. Blood, 2010, 116, 3366-3366.	1.4	0
103	Dysfunctional DNA Double-Strand Break Repair Is Present in a Subset of Primary t-AML/t-MDS Myeloblasts. Blood, 2011, 118, 2415-2415.	1.4	0
104	Mutant U2AF1(S34F) Expression Alters Hematopoiesis in Mice. Blood, 2012, 120, 553-553.	1.4	0
105	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
106	Reduced Hspa9 Expression Alters IL-7 Signaling In B-Cells. Blood, 2013, 122, 1569-1569.	1.4	0
107	Allele-Specific Effects Of U2AF1 Mutations On Alternative Splicing. Blood, 2013, 122, 2748-2748.	1.4	0
108	Knockdown of HSPA9 Induces Apoptosis and Increases TP53 Levels in Human CD34+ Hematopoietic Progenitor Cells. Blood, 2014, 124, 526-526.	1.4	0

#	Article	IF	Citations
109	Detection of Clonal Hematopoiesis in Cytopenic Patients Using Targeted Sequencing. Blood, 2015, 126, 1654-1654.	1.4	0
110	Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients. Blood, 2015, 126, 686-686.	1.4	0
111	The Role of H2AFY in U2AF1 Mutant Cells and Normal Hematopoiesis. Blood, 2016, 128, 963-963.	1.4	0
112	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0
113	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. Blood, 2019, 134, 4271-4271.	1.4	0
114	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. Blood, 2021, 138, 800-800.	1.4	0
115	Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML. Blood, 2020, 136, 2-3.	1.4	0
116	Mutant TRP53-R172H Has Gain-of-Function or Dominant-Negative Effects in Response to Different Hematopoietic Stressors in Mice. Blood, 2020, 136, 1-1.	1.4	0